The University of British Columbia

La Jolla Pharmaceutical Company

Seneb Biosciences, Inc.

Stephen G Withers

Andrew Graham Watts

Tom Wennekes

Jin Hyo Kim

Gary D Brayer

Lloyd MacKenzie

Qingping Wang

Raymond John Andersen

Karl Frank Johnson

Brenda Lougheed

Leslie Karen Williams

Mark Vaughan

Andrew Tarling

Hongming Chen

Ricardo Resende

Jennifer Lois Breschkin

Shawn DeFrees

Shawn Defrees

Thomas J Morley

Christina Rose Tysoe

Zhizeng Gao

Xiaohua Zhang

Katherine Woods

Lars Baumann

Robert Keyzers

Andrew C Tarling

Gary Brayer

Provided herein are compounds having the structure of Formulas A-D and compositions thereof for use in the detection and quantification of viral neuraminidase. In particular, the compounds may be useful for the evaluation of viral strains and for vaccine evaluation.

Compositions and methods for neuraminidase detection and quantification

There are provided compounds of Formula I: various compositions thereof and methods for their use in the inhibition of &#x3b1;-amylase.

Amylase inhibitor compounds, methods of their use and compositions thereof

Provided are methods, uses and pharmaceutical compositions for inhibition of mammalian alpha-amylase in a subject, with a Helianthamide peptide or a derivative thereof in a biologically effective amount. The subject in need of alpha-amylase inhibition, may have or be at risk of developing one or more of the following: Middleton syndrome; a motility disorder of the gastrointestinal tract; postprandial reactive hypoglycemia; postprandial syndrome; irritable bowel syndrome; diabetes mellitus type 1; diabetes mellitus type 2; pre-diabetes; obesity, dumping syndrome; infant dumping syndrome; polycystic ovary syndrome; steatohepatitis; and viral infection.

Mammalian glucosidase inhibitors, methods for their use and pharmaceutical compositions thereof

The present invention relates to a novel endoglycoceramidase whose hydrolytic activity has been substantially reduced or eliminated, such that the enzyme is useful for synthesis of glycolipids from a monosaccharide or oligosaccharide and a ceramide. More specifically, the endoglycoceramidase is a mutant version of a naturally occurring endoglycoceramidase, preferably comprising a mutation within the active site or the nucleophilic site of the enzyme and more preferably comprising a substitution mutation of the Glu residue within the active site or the nucleophilic site. Also disclosed are a method for generating the mutant endoglycoceramidase and a method for enzymatically synthesizing glycolipids using this mutant enzyme.

Mutant endoglycoceramidases with enhanced synthetic activity

This invention provides compound having a structure of Formulas: Furthermore, methods and uses of such compounds for covalently bonding to a sugar acceptor, to form modified protein therapeutics having reduced enzymatic hydrolysis, improved biological stability or an improved pharmacokinetic property. 

Hydrolysis resistant sialic acid derivatives and methods for their use

Equatorial 2,3-fluorinated glycosides compounds of formula (I) useful for the treatment or prophylaxis of viral infection, particularly viral influenza, the methods for their preparation, and their pharmaceutical compositions are provided. The therapeutic effect is achieved via inhibition of viral neuraminidases.

3' equatorial-fluorine-substituted neuraminidase inhibitor compounds, compositions and methods for the use thereof as anti-virals

Compounds having a structure of Formula I and compositions comprising these compounds are provided. Uses of such compounds and compositions are provided for treatment or prophylaxis of viral infection. In particular, compounds and compositions may be for use in the treatment or prophylaxis of viral influenza.

Neuraminidase inhibitor compounds, compositions and methods for the use thereof in anti-viral treatments

Equatorial 2,3-fluorinated glycosides compounds of formula (I) useful for the treatment or prophylaxis of viral infection, particularly viral influenza, the methods for their preparation, and their pharmaceutical compositions. The therapeutic effect is achieved via inhibition of viral neuraminidases. 

3' Equatorial-fluorine-substituted neuraminidase inhibitor compounds, compositions and methods for the use thereof as anti-virals

2,3-Fluorinated glycosides as neuraminidase inhibitors and their use as anti-virals

2,3-fluorinated glycosides as neuraminidase inhibitors and their use as anti-virals

Compounds of structural formula (I) useful for the treatment or prophylaxis of viral infection, particularly viral influenza are provided Pharmaceutical preparations thereof and methods for their preparation are also described. The therapeutic effect is achieved via inhibition of viral neuraminidases, also known as viral sialidases. These neuraminidases are classified under the GH34 family of viral enzymes. 

Particular naturally occurring glycosylated acyl-flavonols are now shown to be effective mammalian &#x3b1;-amylase inhibitors. Such compounds can be obtained from plants of the genusand the compounds are useful in controlling starch digestion such as for management of glycemia in pre-diabetic or diabetic subjects, for management of obesity or for inhibiting oral caries or plaque formation.

Alpha-amylase inhibitors: the montbretins and uses thereof

Growing community of inventors

Vancouver, Canada

Stephen G Withers